Ann: China NMPA Accepts Registration for SpiroSonic Spirometers, page-10

Its common to see 'market inefficiencies' in nanocaps. And particularly in biotechs because many institutional investors avoid them totally and SP is very influenced by traders. I wouldn't be surprised if there is some movement related to traders around the upcoming FDA approval.
At first I found it odd and offputting that key employees are renumerated in shares rather than wages, but considering how they have stuck by the company even when its SP foundered I think this indicates how much they believe in its prospects and obviously some of them are very clever so I think this is a good sign.